Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

INTRODUCTION: Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. CASE PRESENTATIO...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Keita, Iimura, Yasumasa, Hiruma, Kiyoshi, Touma, Tsuguhiro, Tsukamoto, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292183/
https://www.ncbi.nlm.nih.gov/pubmed/32743434
http://dx.doi.org/10.1002/iju5.12099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292183/
https://www.ncbi.nlm.nih.gov/pubmed/32743434
http://dx.doi.org/10.1002/iju5.12099

Ejemplares similares